文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

难治性脓毒性休克血管加压素负荷试验(VALOR)研究:一项前瞻性观察性研究

The Vasopressin Loading for Refractory septic shock (VALOR) study: a prospective observational study.
PubMed 文献 · Crit Care · 2023-07-21
一句话结论对使用≥0.2 μg/kg/min去甲肾上腺素的脓毒性休克患者,血管加压素负荷后MAP变化>22 mmHg可能预测持续输注后儿茶酚胺指数下降,且缺血事件发生率5.4%。

该前瞻性观察性研究纳入接受≥0.2 μg/kg/min去甲肾上腺素治疗的脓毒性休克患者,静脉给予血管加压素1 U负荷后以1 U/h持续输注,根据负荷后平均动脉压(MAP)变化将患者分为应答者(MAP变化>22 mmHg)与非应答者。主要终点为6小时后儿茶酚胺指数(CAI)变化,应答者CAI中位变化为-10,非应答者为0(p<0.0001)。负荷后MAP变化预测持续输注后CAI变化<0的AUROC为0.843,敏感性0.92,特异性0.77。缺血事件(指端缺血、肠系膜缺血、心肌缺血)发生5例(5.4%)。作者认为血管加压素负荷可安全引入脓毒性休克,并可能用于预测持续输注的反应。

要点

  • 对使用≥0.2 μg/kg/min去甲肾上腺素的脓毒性休克患者,血管加压素负荷后MAP变化>22 mmHg定义为应答者,共62例。
  • 应答者6小时CAI中位变化为-10,非应答者为0,前者显著更低(p<0.0001)。
  • 负荷后MAP变化预测持续输注后CAI变化<0的AUROC为0.843,敏感性0.92,特异性0.77。
  • 住院期间缺血事件(指端、肠系膜、心肌缺血)发生5例(5.4%)。
  • 非应答者血促肾上腺皮质激素水平显著更高;应答者负荷前每搏量变异度更高,负荷后每搏量和dP/dtmax更高。

适用人群与场景

  • 接受≥0.2 μg/kg/min去甲肾上腺素治疗的脓毒性休克患者。
  • 研究为前瞻性观察性研究,共登记并检查92例患者。

诊断标准与关键阈值

  • 根据血管加压素负荷后MAP变化分类:MAP变化>22 mmHg为应答者,其余为非应答者。
  • 以MAP变化的较低三分位数作为截断值。

处置流程与药物剂量

  • 血管加压素负荷:静脉给予1 U负荷量,随后以1 U/h持续输注。
  • 在血管加压素负荷前立即进行动脉压力波形分析和内分泌学检测。
  • 主要终点为负荷后6小时儿茶酚胺指数(CAI)变化。

红旗征与不能漏的情况

  • 住院期间前瞻性系统记录指端缺血、肠系膜缺血和心肌缺血作为不良事件,共观察5例(5.4%)。

研究设计与关键结果

  • 研究类型:前瞻性观察性研究;样本量92例;人群:接受≥0.2 μg/kg/min去甲肾上腺素治疗的脓毒性休克患者;干预:血管加压素1 U静脉负荷后1 U/h持续输注。
  • 62例MAP变化>22 mmHg者为应答者,其余为非应答者。
  • 应答者6小时CAI中位变化为-10,非应答者为0,前者显著更低(p<0.0001)。
  • 负荷后MAP变化预测持续输注后CAI变化<0的AUROC为0.843,敏感性0.92,特异性0.77。
  • 非应答者血促肾上腺皮质激素水平显著更高。
  • 应答者负荷前每搏量变异度更高;负荷后每搏量和dP/dtmax更高。
  • 缺血事件发生5例(5.4%)。

证据类型、等级与局限

  • 证据类型:前瞻性观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为血管加压素负荷可安全用于脓毒性休克。
  • 作者认为血管加压素负荷可用于预测对其持续输注的反应,并选择适当的升压策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Vasopressin is a second-line vasoactive agent for refractory septic shock. Vasopressin loading is not generally performed because of the lack of evidence for its effects and safety. However, based on our previous findings, we hypothesized it can predict the responsibility to vasopressin infusion with safety, and prospectively examined it in the present study.

METHODS: Vasopressin loading was performed via the intravenous administration of a bolus of 1 U, followed by its continuous infusion at 1U/h in patients with septic shock treated with ≥ 0.2 μg/kg/min noradrenaline. An arterial pressure wave analysis was conducted, and endocrinological tests were performed immediately prior to vasopressin loading. We classified patients into responders/non-responders based on mean arterial pressure (MAP) changes after vasopressin loading. Based on our previous findings, the lower tertile of MAP changes was selected as the cut-off. The change in the catecholamine index (CAI) after 6 h was assigned as the primary outcome. Digital ischemia, mesenteric ischemia, and myocardial ischemia during the admission period were prospectively and systematically recorded as adverse events.

RESULTS: Ninety-two patients were registered during the study period and examined. Sixty-two patients with a MAP change > 22 mmHg were assigned as responders and the others as non-responders. Blood adrenocorticotropic hormone levels were significantly higher in non-responders. Stroke volume variations were higher in responders before loading, while stroke volume and dP/dtmax were higher in responders after loading. Median CAI changes were - 10 in responders and 0 in non-responders, which was significantly lower in the former (p < 0.0001). AUROC of MAP change with vasopressin loading to predict CAI change < 0 after continuous infusion was 0.843 with sensitivity of 0.92 and specificity of 0.77. Ischemia events were observed in 5 cases (5.4%).

CONCLUSIONS: Vasopressin loading may be safely introduced for septic shock. Vasopressin loading may be used to predict responses to its continuous infusion and select appropriate strategies to increase blood pressure.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Nakamura K, Nakano H, Ikechi D, et al. The Vasopressin Loading for Refractory septic shock (VALOR) study: a prospective observational study. Crit Care. 2023. PMID: 37480126. doi:10.1186/s13054-023-04583-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。